Oral Dosage Form New Animal Drugs; Pergolide, 15960-15961 [2012-6544]
Download as PDF
15960
Federal Register / Vol. 77, No. 53 / Monday, March 19, 2012 / Rules and Regulations
Appendix to Part 163—Interim (a)(1)(A)
List
have in support of a claim for
preferential tariff treatment under the
United States-Korea Free Trade
Agreement (UKFTA), including a
UKFTA importer’s certification.
*
*
*
*
*
*
*
*
*
*
IV. * * *
10. The appendix to part 163 is
amended by adding a new listing under
section IV in numerical order to read as
follows:
■
*
11. The authority citation for part 178
continues to read as follows:
■
§ 10.1005 UKFTA records that the importer
may have in support of a UKFTA claim for
preferential tariff treatment, including an
importer’s certification.
*
PART 178—APPROVAL OF
INFORMATION COLLECTION
REQUIREMENTS
*
*
*
Authority: 5 U.S.C. 301; 19 U.S.C. 1624; 44
U.S.C. 3501 et seq.
12. Section 178.2 is amended by
adding new listings for ‘‘§§ 10.1003 and
10.1004’’ to the table in numerical order
to read as follows:
■
§ 178.2
19 CFR Section
Description
*
*
§§ 10.1003 and 10.1004 ................
*
*
*
Claim for preferential tariff treatment under the US-Korea Free
Trade Agreement.
*
*
*
*
*
*
*
*
David V. Aguilar,
Acting Commissioner, U.S. Customs and
Border Protection.
Approved: March 14, 2012.
Timothy E. Skud,
Deputy Assistant Secretary of the Treasury.
[FR Doc. 2012–6554 Filed 3–15–12; 8:45 am]
BILLING CODE 9111–14–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
21 CFR Part 520
[Docket No. FDA–2011–N–0003]
Oral Dosage Form New Animal Drugs;
Pergolide
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Final rule.
The Food and Drug
Administration (FDA) is amending the
animal drug regulations to reflect
approval of an original new animal drug
application (NADA) filed by Boehringer
Ingelheim Vetmedica, Inc. The NADA
provides for the veterinary prescription
use of pergolide mesylate tablets in
horses for the control of clinical signs
associated with Pituitary Pars
Intermedia Dysfunction (Equine
Cushing’s Disease).
DATES: This rule is effective March 19,
2012.
FOR FURTHER INFORMATION CONTACT:
Amy L. Omer, Center for Veterinary
Medicine (HFV–114), Food and Drug
SUMMARY:
emcdonald on DSK29S0YB1PROD with RULES
Listing of OMB control numbers.
VerDate Mar<15>2010
11:27 Mar 16, 2012
Jkt 226001
*
OMB Control No.
Frm 00028
Fmt 4700
Sfmt 4700
*
1651–0117
*
*
Administration, 7500 Standish Pl.,
Rockville, MD 20855, 240–276–8336,
email: amy.omer@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
Boehringer Ingelheim Vetmedica, Inc.,
2621 North Belt Highway, St. Joseph,
MO 64506–2002, filed NADA 141–331
for the veterinary prescription use in
horses of PRASCEND (pergolide
mesylate) Tablets for the control of
clinical signs associated with Pituitary
Pars Intermedia Dysfunction (Equine
Cushing’s Disease). The NADA is
approved as of September 7, 2011, and
21 CFR part 520 is amended to reflect
the approval.
In accordance with the freedom of
information provisions of 21 CFR part
20 and 21 CFR 514.11(e)(2)(ii), a
summary of safety and effectiveness
data and information submitted to
support approval of this application
may be seen in the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852, between
9 a.m. and 4 p.m., Monday through
Friday.
Under section 512(c)(2)(F)(i) of the
Federal Food, Drug, and Cosmetic Act
(21 U.S.C. 360b(c)(2)(F)(i)), this
approval qualifies for 5 years of
marketing exclusivity beginning on the
date of approval.
The Agency has determined under
21 CFR 25.33 that this action is of a type
that does not individually or
cumulatively have a significant effect on
the human environment. Therefore,
neither an environmental assessment
nor an environmental impact statement
is required.
This rule does not meet the definition
of ‘‘rule’’ in 5 U.S.C. 804(3)(A) because
PO 00000
*
*
it is a rule of ‘‘particular applicability.’’
Therefore, it is not subject to the
congressional review requirements in
5 U.S.C. 801–808.
List of Subjects in 21 CFR Part 520
Animal drugs.
Therefore, under the Federal Food,
Drug, and Cosmetic Act and under
authority delegated to the Commissioner
of Food and Drugs and redelegated to
the Center for Veterinary Medicine,
21 CFR part 520 is amended as follows:
PART 520—ORAL DOSAGE FORM
NEW ANIMAL DRUGS
1. The authority citation for 21 CFR
part 520 continues to read as follows:
■
Authority: 21 U.S.C. 360b.
■
2. Add § 520.1705 to read as follows:
§ 520.1705
Pergolide.
(a) Specifications. Each tablet
contains 1 milligram (mg) pergolide
mesylate.
(b) Sponsor. See No. 000010 in
§ 510.600(c) of this chapter.
(c) Conditions of use in horses—(1)
Amount. Administer orally at a starting
dose of 2 micrograms/kilograms (m/kg)
once daily. Dosage may be adjusted to
effect, not to exceed 4 mg/kg daily.
(2) Indications for use. For the control
of clinical signs associated with
Pituitary Pars Intermedia Dysfunction
(Equine Cushing’s Disease).
(3) Limitations. Federal law restricts
this drug to use by or on the order of
a licensed veterinarian.
E:\FR\FM\19MRR1.SGM
19MRR1
Federal Register / Vol. 77, No. 53 / Monday, March 19, 2012 / Rules and Regulations
Dated: March 14, 2012.
Bernadette Dunham,
Director, Center for Veterinary Medicine.
nor an environmental impact statement
is required.
Under section 512(c)(2)(F)(i) of the
Federal Food, Drug, and Cosmetic Act
(21 U.S.C. 360b(c)(2)(F)(i)), this
approval qualifies for 5 years of
marketing exclusivity beginning on the
date of approval.
This rule does not meet the definition
of ‘‘rule’’ in 5 U.S.C. 804(3)(A) because
it is a rule of ‘‘particular applicability.’’
Therefore, it is not subject to the
congressional review requirements in
5 U.S.C. 801–808.
[FR Doc. 2012–6544 Filed 3–16–12; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
21 CFR Part 520
[Docket No. FDA–2011–N–0003]
Oral Dosage Form New Animal Drugs;
Phenylpropanolamine
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Final rule.
The Food and Drug
Administration (FDA) is amending the
animal drug regulations to reflect
approval of an original new animal drug
application (NADA) filed by Pegasus
Laboratories, Inc. The NADA provides
for the veterinary prescription use of
phenylpropanolamine hydrochloride
chewable tablets for the control of
urinary incontinence due to urethral
sphincter hypotonus in dogs.
DATES: This rule is effective March 19,
2012.
FOR FURTHER INFORMATION CONTACT: Lisa
M. Troutman, Center for Veterinary
Medicine (HFV–116), Food and Drug
Administration, 7500 Standish Pl.,
Rockville, MD 20855, 240–276–8322,
email: lisa.troutman@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Pegasus
Laboratories, Inc., 8809 Ely Rd.,
Pensacola, FL 32514, filed NADA 141–
324 that provides for the veterinary
prescription use of PROIN
(phenylpropanolamine hydrochloride)
Chewable Tablets for the control of
urinary incontinence due to urethral
sphincter hypotonus in dogs. The
NADA is approved as of August 4, 2011,
and the regulations are amended in
21 CFR part 520 to reflect the approval.
A summary of safety and effectiveness
data and information submitted to
support approval of this application
may be seen in the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852, between
9 a.m. and 4 p.m., Monday through
Friday.
The agency has determined under
21 CFR 25.33 that this action is of a type
that does not individually or
cumulatively have a significant effect on
the human environment. Therefore,
neither an environmental assessment
emcdonald on DSK29S0YB1PROD with RULES
SUMMARY:
VerDate Mar<15>2010
11:27 Mar 16, 2012
Jkt 226001
List of Subjects in 21 CFR Part 520
Animal drugs.
Therefore, under the Federal Food,
Drug, and Cosmetic Act and under
authority delegated to the Commissioner
of Food and Drugs and redelegated to
the Center for Veterinary Medicine,
21 CFR part 520 is amended as follows:
PART 520—ORAL DOSAGE FORM
NEW ANIMAL DRUGS
1. The authority citation for 21 CFR
part 520 continues to read as follows:
■
Authority: 21 U.S.C. 360b.
■
2. Add § 520.1760 to read as follows:
§ 520.1760
Phenylpropanolamine.
(a) Specifications. Each chewable
tablet contains 25, 50, or 75 milligram
(mg) phenylpropanolamine
hydrochloride.
(b) Sponsors. See No. 055246 in
§ 510.600(c) of this chapter.
(c) Conditions of use in dogs—(1)
Amount. Administer 2 mg/kg of body
weight twice daily.
(2) Indications for use. For the control
of urinary incontinence due to urethral
sphincter hypotonus in dogs.
(3) Limitations. Federal law restricts
this drug to use by or on the order of
a licensed veterinarian.
Dated: March 14, 2012.
Bernadette Dunham,
Director, Center for Veterinary Medicine.
[FR Doc. 2012–6553 Filed 3–16–12; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
21 CFR Chapter I
[Docket No. FDA–2012–N–0222]
Revision of Organization and
Conforming Changes to Regulations
AGENCY:
Food and Drug Administration,
HHS.
PO 00000
Frm 00029
Fmt 4700
Sfmt 4700
ACTION:
15961
Final rule.
The Food and Drug
Administration (FDA) is issuing this
final rule to amend the regulations to
reflect organizational change in the
Agency and to make other conforming
changes. This action is editorial in
nature and is intended to improve the
accuracy of the Agency’s regulations.
DATES: This rule is effective April 1,
2012.
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Vanessa Starks, Human Capital
Management, Food and Drug
Administration, 19903 New Hampshire
Ave., Silver Spring, MD 20903, 301–
796–8846.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is issuing this final rule to
amend its regulations by updating the
organizational information in part 5
(21 CFR part 5).
The portion of this final rule updating
the organizational information in part 5,
subpart M is a rule of Agency
organization, procedure, or practice.
FDA is issuing these provisions as a
final rule without publishing a general
notice of proposed rulemaking because
such notice is not required for rules of
Agency organization, procedure, or
practice under 5 U.S.C. 553(b)(3)(A). For
the conforming changes to the other
regulations, the Agency finds good
cause under 5 U.S.C. 553(b)(3)(B) to
dispense with prior notice and
comment, and good cause under 5
U.S.C. 553(d)(3) to make these
conforming changes effective less than
30 days after publication because such
notice and comment and delayed
effective date are unnecessary and
contrary to the public interest. These
conforming changes merely update the
footnotes in part 5, subpart M. These
changes do not result in any substantive
change in the regulations.
II. Analysis of Impacts
FDA has examined the impacts of the
final rule under Executive Order 12866,
Executive Order 13563, the Regulatory
Flexibility Act (5 U.S.C. 601–612), and
the Unfunded Mandates Reform Act of
1995 (Pub. L. 104–4). Executive Orders
12866 and 13563 direct Agencies to
assess all costs and benefits of available
regulatory alternatives and, when
regulation is necessary, to select
regulatory approaches that maximize
net benefits (including potential
economic, environmental, public health
and safety, and other advantages;
distributive impacts; and equity). The
Agency believes that this final rule is
E:\FR\FM\19MRR1.SGM
19MRR1
Agencies
[Federal Register Volume 77, Number 53 (Monday, March 19, 2012)]
[Rules and Regulations]
[Pages 15960-15961]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-6544]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Part 520
[Docket No. FDA-2011-N-0003]
Oral Dosage Form New Animal Drugs; Pergolide
AGENCY: Food and Drug Administration, HHS.
ACTION: Final rule.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is amending the animal
drug regulations to reflect approval of an original new animal drug
application (NADA) filed by Boehringer Ingelheim Vetmedica, Inc. The
NADA provides for the veterinary prescription use of pergolide mesylate
tablets in horses for the control of clinical signs associated with
Pituitary Pars Intermedia Dysfunction (Equine Cushing's Disease).
DATES: This rule is effective March 19, 2012.
FOR FURTHER INFORMATION CONTACT: Amy L. Omer, Center for Veterinary
Medicine (HFV-114), Food and Drug Administration, 7500 Standish Pl.,
Rockville, MD 20855, 240-276-8336, email: amy.omer@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Boehringer Ingelheim Vetmedica, Inc., 2621
North Belt Highway, St. Joseph, MO 64506-2002, filed NADA 141-331 for
the veterinary prescription use in horses of PRASCEND (pergolide
mesylate) Tablets for the control of clinical signs associated with
Pituitary Pars Intermedia Dysfunction (Equine Cushing's Disease). The
NADA is approved as of September 7, 2011, and 21 CFR part 520 is
amended to reflect the approval.
In accordance with the freedom of information provisions of 21 CFR
part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and
effectiveness data and information submitted to support approval of
this application may be seen in the Division of Dockets Management
(HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.
Under section 512(c)(2)(F)(i) of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 360b(c)(2)(F)(i)), this approval qualifies for
5 years of marketing exclusivity beginning on the date of approval.
The Agency has determined under 21 CFR 25.33 that this action is of
a type that does not individually or cumulatively have a significant
effect on the human environment. Therefore, neither an environmental
assessment nor an environmental impact statement is required.
This rule does not meet the definition of ``rule'' in 5 U.S.C.
804(3)(A) because it is a rule of ``particular applicability.''
Therefore, it is not subject to the congressional review requirements
in 5 U.S.C. 801-808.
List of Subjects in 21 CFR Part 520
Animal drugs.
Therefore, under the Federal Food, Drug, and Cosmetic Act and under
authority delegated to the Commissioner of Food and Drugs and
redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is
amended as follows:
PART 520--ORAL DOSAGE FORM NEW ANIMAL DRUGS
0
1. The authority citation for 21 CFR part 520 continues to read as
follows:
Authority: 21 U.S.C. 360b.
0
2. Add Sec. 520.1705 to read as follows:
Sec. 520.1705 Pergolide.
(a) Specifications. Each tablet contains 1 milligram (mg) pergolide
mesylate.
(b) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter.
(c) Conditions of use in horses--(1) Amount. Administer orally at a
starting dose of 2 micrograms/kilograms ([mu]/kg) once daily. Dosage
may be adjusted to effect, not to exceed 4 [mu]g/kg daily.
(2) Indications for use. For the control of clinical signs
associated with Pituitary Pars Intermedia Dysfunction (Equine Cushing's
Disease).
(3) Limitations. Federal law restricts this drug to use by or on
the order of a licensed veterinarian.
[[Page 15961]]
Dated: March 14, 2012.
Bernadette Dunham,
Director, Center for Veterinary Medicine.
[FR Doc. 2012-6544 Filed 3-16-12; 8:45 am]
BILLING CODE 4160-01-P